ChristianaCare

All visitors are required to wear masks.

For COVID-19 safety, all visitors to ChristianaCare facilities and services are required to wear masks. This includes visitors who are vaccinated. Please read our visitor guidelines before arrival.

Masks required at outpatient locations; visitors and support persons limited

All visitors at outpatient locations must be masked in alignment with the masking guidelines on our visitation policy page here. Patients at ChristianaCare’s outpatient services are advised to come to their appointments alone unless a support person is absolutely needed. If a support person is needed, such as a parent, guardian or spokesperson, we highly encourage that the support person be vaccinated. Outpatient practices are not requiring vaccination or a negative COVID test for visitors at this time.

All hospital visitors required to be vaccinated or have a negative COVID-19 test.

  • Inpatients in our Christiana, Wilmington and Union hospitals may have one visitor daily between 10 a.m. and 8 p.m. The visitor must be 16 or older.
  • Patients having outpatient surgery may have one support person accompany them. Support persons must be 16 or older.
  • All visitors and surgical support people must show proof of vaccination OR a negative COVID-19 test within the prior 72 hours.

Before visiting, click here for more details about visitation.

Visit coronavirus.delaware.gov or cecilcountyhealth.org for local vaccination and testing sites.

Cancer Research at the
Helen F. Graham Cancer Center
& Research Institute

NCORP and Pharmaceutical Clinical Trials

NCORP Clinical Trials

In 1987, ChristianaCare was awarded funding as a Community Clinical Oncology Program (CCOP), which provided the opportunity for physicians throughout Delaware to enroll patients in national clinical trials. Additionally, it offered an opportunity to increase minority and underserved community clinical trial participation. Since joining CCOP, the Helen F. Graham Cancer Center & Research Institute has become one of the largest clinical trial programs among community-based hospitals in the country, with some 100 active clinical trials in most kinds of cancer. The Graham Cancer Center is also one of the top enrollers in cancer clinical trials.

In 2014, a number of CCOP’s merged to form NCORP, the National Cancer Institute’s Community Oncology Research Program. NCORP is a national network of investigators, cancer care providers, academic institutions, and other organizations. NCORP continues the work of CCOP’s by offering multi-site cancer clinical trials and studies to diverse populations in community-based healthcare systems across the United States and Puerto Rico. The goal of NCORP is to bring cancer clinical trials – cancer control, prevention, screening, treatment, and imaging – as well as cancer care delivery research, to individuals in their own communities, thus generating a broadly applicable evidence base that contributes to improved patient outcomes and a reduction in cancer disparities.

The mission of the Graham Cancer Center is to reduce the incidence, morbidity and mortality of cancer in our community and to improve quality of life for those living with cancer. Participation in NCORP helps us to realize these goals.

Pharmaceutical Clinical Trials

The Graham Cancer Center offers a robust pharmaceutical trials program that conducts Phase I, II and III chemotherapy and immunotherapy trials in collaboration with private industry and university research centers across the country. Many of these studies give our patients the opportunity for leading-edge cancer treatments, tailored to their particular cancer without leaving our community.

Cancer Research Program
Helen F. Graham Cancer Center & Research Institute
4701 Ogletown-Stanton Road, Suite 2200, Newark, DE 19713 directions
For more information, call 302-623-4450 or e-mail us.